Sander A. Flaum MM+M - Medical Marketing and Media

Sander A. Flaum

Most recent articles by Sander A. Flaum

Pharmacies are getting a bad name when price myopia is the real culprit
Pharmacies are getting a bad name when price myopia is the real culprit
Sander A. Flaum
April 3, 2020
5:00 am

A recent New York Times article took aim at pharmacies, but the major problem going unresolved is price myopia.

The next big thing in pharma might not be something you like
The next big thing in pharma might not be something you like
Sander A. Flaum
March 24, 2020
2:41 pm

Hospitals competing on pharma’s turf by supplying their own generics signals a tectonic shift, and don’t expect it to go away anytime soon.

Forget about pharma profits and focus on drug tort reform
Forget about pharma profits and focus on drug tort reform
Sander A. Flaum
January 10, 2020
5:00 am

While many critics are quick to point to a pharma company’s profits, you don’t hear enough about the money being made by the drug tort industry.

It’s time to push back on drug price legislation
It’s time to push back on drug price legislation
Sander A. Flaum
November 6, 2019
5:00 am

Sander Flaum wants pharma to push back on pricing legislation.

Want to save money on drug prices? Don’t listen to Washington
Want to save money on drug prices? Don’t listen to Washington
Sander A. Flaum
October 2, 2019
5:00 am

Sander Flaum urges Americans to ignore politicians’ calls to head north of the border for their prescription medication.

Healthcare system won’t be fixed by lower drug prices alone
Healthcare system won’t be fixed by lower drug prices alone
Sander A. Flaum
September 6, 2019
5:00 am

Even if drug manufacturers lower prices, it won’t fix the U.S healthcare system.

Was President Trump’s plan to reduce drug prices DOA?
Was President Trump’s plan to reduce drug prices DOA?
Sander A. Flaum
February 7, 2019
6:00 am

President Trump’s blueprint to lower drug prices hasn’t made it out of the brainstorm phase.

Critics who want to cut drug prices must say which ones
Critics who want to cut drug prices must say which ones
Sander A. Flaum
January 3, 2019
6:00 am

Cutting prescription drug prices has become one of the most popular campaign promises of our time.

Paying Lip Service to STEM Isn’t Enough
Paying Lip Service to STEM Isn’t Enough
Sander A. Flaum
November 22, 2016
9:00 pm

I’m not suggesting that colleges become vocational schools. But don’t you think they should also help young people prepare for the life they’re going to be living?

Will Investors Reward Drugmakers That Limit Price Increases?
Will Investors Reward Drugmakers That Limit Price Increases?
Sander A. Flaum
October 24, 2016
12:00 pm

Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?

  • Culture drives the company

    Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.

  • From Our Partners